CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to REGN

REGN17372+Linvoseltamab

Phase 2
Regeneron Pharmaceuticals, Inc. (REGN)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Relapsed Refractory Multiple Myeloma (RRMM)

View Full Landscape
Drug Information

Target Indication

Relapsed Refractory Multiple Myeloma (RRMM)

Clinical Trial

NCT07455851

Last updated: 6/25/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.